key: cord-0963892-g1b431ci
authors: Futatsugi, Hiroyuki; Iwabu, Masato; Okada-Iwabu, Miki; Okamoto, Koh; Amano, Yosuke; Morizaki, Yutaka; Kadowaki, Takashi; Yamauchi, Toshimasa
title: Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19
date: 2020-10-28
journal: Front Cardiovasc Med
DOI: 10.3389/fcvm.2020.593061
sha: 4869c3963cad7008ac973155547e566cdee08ade
doc_id: 963892
cord_uid: g1b431ci

Since December 2019, coronavirus disease 2019 (COVID-19) caused by a novel coronavirus has spread all over the world affecting tens of millions of people. Another pandemic affecting the modern world, type 2 diabetes mellitus is among the major risk factors for mortality from COVID-19. Current evidence, while limited, suggests that proper blood glucose control may help prevent exacerbation of COVID-19 even in patients with type 2 diabetes mellitus. Under current circumstances where the magic bullet for the disease remains unavailable, it appears that the role of blood glucose control cannot be stressed too much. In this review the profile of each anti-diabetic agent is discussed in relation to COVID-19.

multiple large-scaled studies show that their use affected none of these rates (9) (10) (11) . Actually, at present, almost all medical associations, including the International Society of Hypertension, American College of Cardiology, American Heart Association and Heart Failure Society of America, have published statements recommending the continued use of ACE inhibitors and ARBs (12, 13) .

COVID-19 is thought unlikely to become severe in a majority of cases. In fact, a recent meta-analysis of 47,344 patients with COVID-19 in China shows that the risks of severity and mortality were 18.0 and 3.2%, respectively, among these patients, while these rates increased if patients had comorbidities (14) .

Diabetes mellitus is another global pandemic affecting 463 million people worldwide (15) . In the face of the COVID-19 pandemic, two facts need to be taken to heart. First, nutrition and exercise therapy represent the cornerstone of diabetes management (16) . However, the resultant need for home confinement to control the pandemic, as well as for a new lifestyle to reduce the risk of infection, is shown to reduce physical activity and increase sweet food consumption (17, 18) , while, now more than ever, the importance of healthy diet and exercise needs to be stressed. Second, which concerns the main theme of this review, diabetes is among the comorbidities associated with increased risk of COVID-19 (19) . According to a recent metaanalysis, COVID-19 patients who had diabetes at baseline had increased severity and mortality (HR, 2.11 [CI, 1.40-3.18], 1.69 [CI, 1.22-2.33], respectively), although the prevalence of diabetes in the affected population did not seem to differ from that in the non-affected population in Asia (20) . Fortunately, however, it is indicated in a retrospective multicenter study conducted in China that proper blood glucose control may reduce not only the severity of COVID-19 but mortality from the disease in patients with pre-existing diabetes showing improvements in systemic inflammation as measured by serum inflammation markers (21) . Actually, in the study, during the 28-day observation period, patients with favorable glycemic control (3.9-10 mmol/L) had a significantly lower mortality rate compared to those with poorly glycemic control (the lowest BG level, >3.9 mmol/L or the highest BG level, >10 mmol/L) (HR 0.14 [CI, 0.03-0.60]) (21) . In the current situation where COVID-19 and diabetes are so prevalent that they combine to affect a high proportion of patients and where there is no critical medicine or vaccine for COVID-19, the fact that blood glucose control has a role to play in reducing the severity of the disease as well as mortality from the disease, cannot be stressed too much (21) .

Then, how should we achieve blood glucose control? First, we would suggest that PCR-confirmed asymptomatic type 2 diabetic patients with COVID-19 or those with mild self-limiting COVID-19 should continue with their current prescription because, to date, there is no evidence to suggest that certain glucose-lowering agents interact with or worsen the disease in patients with asymptomatic or mild COVID-19 (22) . This strategy is supported by the fact that hyperglycemia itself is likely to lead to greater severity of COVID-19 and higher mortality from the disease (23, 24) . In patients with moderate to severe symptoms who need hospital admission, however, given the pathophysiological and clinical characteristics of COVID-19, some drugs may not be deemed favorable, due to their side effects that could potentially adversely affect the course of the illness. In this review focused on biguanides, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors and insulin, their profiles will be discussed in relation to COVID-19.

Biguanides, represented by metformin, is one of the most frequently prescribed oral glucose-lowering agents. Metformin mainly functions by activating AMP-activated protein kinase (AMPK) through inhibition of the respiratory chain of mitochondria thereby subsequently reducing gluconeogenesis in the liver (25) . In most situations, metformin is a welltolerated drug with a relatively low rate of adverse effects. However, as it inhibits mitochondrial respiration and increases lactate production, it may induce lactic acidosis in some patients receiving it, with nearly half of all patients developing lactic acidosis dying from it. Of note, while the risk of lactic acidosis is increased in patients with renal or hepatic impairment, dehydration, shock, hypoxic states, sepsis and advanced age (26) , these conditions are often found to be present in patients with severe COVID-19 (27) . In addition, up to half of all hospitalized COVID-19 patients are shown to suffer deep venous thrombosis (DVT) thus often requiring the use of contrast-enhanced CT for DVT assessment (28) . When transient renal impairment occurs following injection of an iodinated contrast agent in patients receiving a biguanide, however, the renal excretion of the drug is decreased, and their lactic acid levels increased, thus placing these patients at risk of lactic acidosis (29) . On the contrary, a recent retrospective study performed in China showed that metformintreated patients hospitalized for COVID-19 had a lower mortality rate compared to non-metformin-treated patients (30, 31) . Thus, overall, while diabetic patients with asymptomatic or mild COVID-19 may continue current metformin therapy and further interventional studies should be conducted to prove or disprove this recommendation, it appears that, as a rule, metformin should be withdrawn in hospitalized patients.

Thiazolidinediones are shown to achieve their blood glucoselowering effect by activating peroxisome proliferator-activated receptor γ (PPARγ ) thereby increasing insulin sensitivity (32) . In addition to their glucose-lowering effects, thiazolidinediones are also shown to exert immunomodulatory effects (33) . Given that immune hyperactivity is considered to be involved in the pathophysiology of COVID-19, it appears reasonable to assume that they may have some positive impact on the disease progression (33) (34) (35) (36) . However, there are also some concerns. First, while its clinical impact is not known, pioglitazone has the potential to enhance ACE2 expression in the liver, adipose tissue and skeletal muscle (37, 38) , suggesting that the use of thiazolidinediones may affect not only the prevalence of COVID-19 but the mortality from the disease. Second, thiazolidinediones also act on the collecting tubule to increase water and sodium reabsorption by enhancing the expression of the epithelial Na + channel, thus causing edema and fluid retention (39, 40) . This adverse effect may be enhanced in patients with COVID-19, given that the disease is sometimes shown to damage the kidneys and myocardium (41, 42). Therefore, it appears that, for the time being at least, it is advisable to avoid using thiazolidinediones in hospitalized patients.

Sulfonylureas, the oldest oral antidiabetic drugs, are shown to promote insulin release from pancreatic β cells by binding to and closing the ATP-sensitive potassium channel resulting in depolarization of the plasma membrane and increased calcium influx thus leading to insulin exocytosis (43) . Again, glinides represent viable options in managing postprandial hyperglycemia due to their rapid and short-lasting insulinotropic effects (44, 45) . However, sulfonylureas are known to cause hypoglycemia at a non-negligible rate with the risk shown to increase in acute settings (46) , thus making their use inappropriate in patients with severe COVID-19.

DPP4 inhibitors exert their anti-diabetic effects by inhibiting DPP4, which degrades incretin hormones, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), thus elevating blood levels of these hormones. Since these hormones stimulate insulin release glucose-dependently, DPP4 inhibitors lower blood glucose levels with no significant risk of hypoglycemia (43) . Although DPP4 is considered to be a functional receptor of MERS-CoV (47), a sibling of SARS-CoV-2, there is no evidence to date to show that it interacts with SARS-CoV-2. Actually, a case control study conducted in Italy showed no association between the exposure to DPP4 inhibitor and the risk of hospitalization due to COVID-19 (48) . Of note, DPP4 inhibitors exert anti-inflammatory effects without increasing the risk of infectious disease and thus may prove protective against COVID-19-induced lung injury (49) (50) (51) . To confirm these hypotheses, a phase 4 clinical trial of linagliptin vs. insulin is currently underway to compare their effectiveness not only in achieving glucose control but in preventing the progression of COVID-19 in type 2 diabetic patients with mild to moderate COVID-19 (52). While, given its glucose-dependent effects and the risk of hypoglycemia thought to be relatively low with this DPP-4 inhibitor, the use of DPP-4 inhibitors as a class may be deemed relatively safe in these patients mild to moderate COVID-19, consideration should be given to switching to insulin in patients with severe COVID-19.

While the mechanism of action of GLP-1R agonists is not fully understood, it seems likely that it involves cAMP signaling pathways and intracellular glucose metabolism in restoring β-cell glucose sensitivity (53) . Due to this mechanism, GLP-1R agonists are assumed to lower blood glucose with relatively low risk of hypoglycemia (54) . In addition, they help reduce food intake and body weight and thus may often be beneficial for diabetic patients who tend to be overweight (53) (54) (55) . Also, their cardioand renoprotective profile may prove beneficial for patients with COVID-19 (56, 57) . In addition, of the GLP-1 agonists, liraglutide has the potential to increase lung ACE2 expression, while the net effect of ACE2 on COVID-19 still remains unknown (58) . Nevertheless, GLP-1R agonists may as well be withdrawn from diabetic patients requiring hospitalization with COVID-19, given that their frequent adverse events, gastrointestinal symptoms (e.g., nausea, diarrhea or vomiting) are likely to worsen dehydration and, as a consequence, cause renal failure, which often occur in patients with COVID-19 (27, 53) .

Unlike other oral glucose-lowering agents described above, this class of drugs exert their effects, independently of insulin, by blocking sodium-glucose cotransporter 2 (SGLT2) in the renal proximal tubules from reabsorbing filtered glucose, i.e., by increasing glucose excretion thereby decreasing levels of blood glucose (59) . Moreover, SGLT2 inhibitors are known to have cardio-and renoprotective effects (60) (61) (62) and have the potential to improve systemic metabolism, thus possibly preventing respiratory failure and organ dysfunction associated with COVID-19. To test this speculation, a phase 3 international, multicenter, double-blind, randomized, placebo-controlled trial of dapagliflozin is now underway in hospitalized, mild-tomoderate COVID-19 patients with preexisting comorbidities (63) . However, an international expert panel warns that increased glucose excretion may also lead to fluid loss, possibly resulting in worsening of dehydration and onset of diabetic ketoacidosis in diabetic patients with COVID-19 (22, 64) . Based on these findings, therefore, consideration should be given to discontinuing SGLT2 inhibitors in diabetic patients with COVID-19 at high risk of respiratory failure and thrombosis.

The only hormone available to lower blood levels of glucose, insulin is released from pancreatic β cells sensitized by glucose influx through glucose transporter type 2 (GLUT2) and stimulates the uptake of carbohydrates, peptides and lipids by other cells. Simultaneously, it inhibits hepatic gluconeogenesis and glycolysis, thus causing a rapid drop of blood glucose (65, 66) . In normal settings, the goal of insulin therapy is to reproduce physiologic insulin secretion using long-acting analogs as basal insulin release and rapid-acting analogs as prandial insulin release (67) . Unlike other oral antidiabetic agents, insulin has been used in critically ill patients whose prognosis is shown to improve to a greater extent with conventional insulin therapy than with intensive insulin therapy (68, 69) . While insulin therapy prior to admission was shown to be associated with higher mortality in patients with COVID-19 (70, 71) , there is a possibility that blood glucose control with insulin therapy during hospitalization leads to reductions in the risk of sever disease in these patients (72) . Of course, when using insulin, close monitoring of blood glucose levels is essential, because it is sometimes associated with hypoglycemic events thus possibly raising mortality rates in critically ill patients (73, 74) . However, given the current circumstances where there is no accumulated evidence to support the use of other agents, insulin appears to be the best choice for diabetic inpatients with COVID-19.

While the possible harms and benefits of antidiabetic drugs have been summarized in the context of COVID-19, some of these recommendations remain rather hypothetical, because of the paucity of current evidence. Again, several clinical trials are now underway to investigate the actual effect of these drugs in controlling blood glucose diabetic patients with COVID-19, with some of these drugs expected to prevent exacerbation of COVID-19 even in non-diabetic patients. The characteristics of these trials are summarized in Table 1 . These include NCT04341935 and NCT04371978, both randomized open label studies in diabetic patients with COVID-19, with the former intended to prove the efficacy of the investigational drugs in controlling blood glucose, and the latter aimed to reveal the efficacy of the study drugs in improving the severity of the disease (52, 75); NCT04365517, also a randomized controlled open label study designed to investigate the potential respiratory role of the DPP4 inhibitor sitagliptin in diabetic patients suffering from pneumonia due to . Through these studies, DPP4 inhibitors may be shown to be effective in controlling blood glucose in diabetic patients with COVID-19. Again, a non-randomized matching cohort study, NCT04473274 is intended to investigate the safety of the thiazolidinedione pioglitazone in patients with relative hyperglycemia requiring hospital admission due to COVID-19 (77) and may be able to address the speculative concern posed above. NCT04510194 is a large-scale, randomized, quadruple blinded study evaluating metformin not only for its therapeutic but for its preventive role against COVID-19 (78) . Given the large sample size and the reliable study design, as well as the fact that, to date, virtually no drug has been proved to prevent the infection itself, the results of this study are worth paying attention to. Furthermore, another large-scale study, NCT04350593 should be of particular interest, given the unavailability of any established treatment for the disease (63) . Again, overall, the outcomes of these trials may help further optimize blood glucose control strategy for diabetic patients with COVID-19.

The present review was an attempt to summarize the profiles of currently available antidiabetic agents and their role in maintaining blood glucose control in hospitalized diabetic patients with COVID-19. While it remains important to continue current regimens for glucose control in patients with mild, self-limiting COVID-19, it appears that insulin may be a good choice for patients with severe COVID-19, while DPP4 inhibitors may also prove to be a good choice, along with insulin, for patients with mild to moderate disease, pending the results of clinical trials currently underway. At any rate, given that the COVID-19 pandemic is unlikely to end any time soon and that diabetes is closely associated with disease progression, continued efforts need to be made to accumulate evidence that guides the use of antidiabetic agents in diabetic patients with COVID-19 and to establish the best possible approach to achieving blood glucose control in these patients.

HF, MI, MO-I, and TY wrote the manuscript. All authors reviewed the manuscript.

This work was supported by Management Expenses Grants.

A novel coronavirus from patients with pneumonia in China

COVID-19) Outbreak Situation. World Health Organization (2020)

The end of social confinement and COVID-19 re-emergence risk

Time, space and social interactions: exit mechanisms for the Covid-19 epidemics

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Renin-angiotensinaldosterone system blockers and the risk of Covid-19

Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality

Available online at: https:// ish-world

Available online at

Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and metaanalysis

Available online at

Lifestyle management: standards of medical care in diabetes

Metabolic impacts of confinement during the COVID-19 pandemic due to modified diet and physical activity habits

Covid-19 confinement and changes of adolescent's dietary trends in Italy, Spain, Chile, Colombia and Brazil

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis

Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Practical recommendations for the management of diabetes in patients with COVID-19

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes

The mechanisms of action of metformin

Metformin-associated lactic acidosis: current perspectives on causes and risk

Clinical characteristics of coronavirus disease 2019 in China

Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome

Metformin-associated lactic acidosis following contrast media-induced nephrotoxicity

Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis

Metformin and COVID-19: from cellular mechanisms to reduced mortality

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes

Pharmacological (or synthetic) and nutritional agonists of PPAR-gamma as candidates for cytokine storm modulation in COVID-19 disease

The trinity of COVID-19: immunity, inflammation and intervention

Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): boon or bane?

Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses

Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis

Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced non-alcoholic steatohepatitis

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: a randomized controlled trial

COVID-19 and the cardiovascular system

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

International Hypoglycaemia Study G. Minimizing hypoglycemia in diabetes

Debate on insulin vs. noninsulin use in the hospital setting-is it time to revise the guidelines for the management of inpatient diabetes?

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study

Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition

COVID-19 and comorbidities: a role for dipeptidyl peptidase 4 (DPP4) in disease severity?

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

Mechanisms of action and therapeutic application of glucagonlike peptide-1

A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials

Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats

Sodium Glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19)

Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor

Insulin analogues in type 1 diabetes mellitus: getting better all the time

The cell biology of systemic insulin function

New forms of insulin and insulin therapies for the treatment of type 2 diabetes

Intensive versus conventional glucose control in critically ill patients

Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication

Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care

Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia

Hypoglycemia and risk of death in critically ill patients

Available online at: clinicaltrials.gov/ct2/show/NCT04371978 (accessed September 4, 2020). 76. The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients (SIDIACO). (2020)

GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study (GOTCHA). (2020)

Trial-METformin for Prevention and Outpatient Treatment of COVID-19